June 17, 2025

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

Sub: Update on outcome for purpose of integrated financials for the financial year ended March 31, 2025

Find enclosed the outcome with respect to the integrated financials for the financial year ended March 31, 2025 which has already been disclosed to the stock exchanges vide letter dated May 29, 2025.

However, we are hereby informed by the exchange that the Company also requires to upload the outcome, as an 'announcement' for declaration of financial results, hence the signed results are now reproduced for purpose of capturing the same under the required compliance by the exchange.

Kindly take the same on record.

Thanking you.

For **Procter & Gamble Health Limited**

FLAVIA PETER MACHADO
Digitally signed by FLAVIA PETER MACHADO
Date: 2025.06.17 15:24:24 +05'30'

Flavia Machado
Authorized Signatory

c

May 29, 2025

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

Sub: Outcome of the Board Meeting held on May 29, 2025

We are pleased to inform you that a meeting of the Board of Directors of the Company held today (commenced at 12.40 pm and ended at 5.14 pm), the Audited Financial Results for the Financial Year ended March 31,2025 were approved.

We are enclosing herewith the following:

a. Audited Financial Results for the Financial Year ended March 31,2025, as per format prescribed under Regulation 33 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015;
b. Auditor's Report, in respect of the aforementioned Financial Results, as furnished by the Statutory Auditors of the Company;
c. A declaration with respect to Audit Report with unmodified opinion to the aforementioned Audited Financial Results

We are pleased to further inform you that the Board of Directors of the Company at its meeting held today, *inter alia*, have recommended a dividend of Rs. 45 per Equity Share (Nominal Value of Rs. 10/- each), for the Financial Year ended March 31, 2025. The divided shall be paid on or before September 25, 2025, on approval of the Members at the ensuing Annual General Meeting.

Kindly take the same on record.

Thanking you.

For **Procter & Gamble Health Limited**

Zeal Bhavin Rupani
Digitally signed by Zeal Bhavin Rupani
Date: 2025.05.29 17:21:12 +05'30'

Zeal Rupani
Company Secretary

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.
CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND FINANCIAL YEAR (NINE MONTHS) ENDED 31ST MARCH 2025

(₹ in lakhs)

Sr. No.	Particulars	(1) Three months ended 31st March 2025 (Audited) (refer note 5)	(2) Preceding Three months ended 31st December 2024 (Unaudited)	(3) Corresponding Three months ended 31st March 2024 (Unaudited)	(4) Nine months ended 31st March 2025 (Audited) (refer note 4)	(5) Corresponding Nine months ended 31st March 2024 (Unaudited) (refer note 5)	(6) Previous Year ended 30th June 2024 (Audited)
1.	**Revenue from Operations**	31 099	30 977	25 248	93 417	86 738	115 126
2.	**Other Income**	311	396	227	1 035	1 350	1 563
3.	**Total income (1+2)**	31 410	31 373	25 475	94 452	88 088	116 689
	Expenses						
	a) Cost of materials consumed	9 082	6 160	6 466	20 059	22 281	29 023
	b) Purchases of stock-in-trade (Traded goods)	1 372	1 328	1 113	4 716	2 095	3 946
	c) Changes in inventories of finished goods,work-in-progress and stock in trade	(582)	85	(193)	1 475	763	87
	d) Employee benefits expenses	4 879	4 705	4 846	14 206	16 653	21 516
	e) Depreciation and amortisation expenses	537	555	684	1 669	2 024	2 740
	f) Finance costs	13	15	15	43	52	72
	g) Other expenses	8 256	6 356	6 272	21 122	19 171	29 954
4.	**Total expenses (4)**	23 557	19 204	19 203	63 290	63 039	87 338
5.	**Profit before exceptional items and tax (3-4)**	7 853	12 169	6 272	31 162	25 049	29 351
6.	Less: Exceptional items (refer note 8)	-	-	-	-	-	2 019
7.	**Profit before tax (5-6)**	7 853	12 169	6 272	31 162	25 049	27 332
8.	**Tax expenses**						
	a) Current Tax	2 064	2 904	1 630	7 763	6 631	7 910
	b) Deferred Tax Charge / (Credit)	(336)	175	(14)	(49)	(186)	(860)
	c)Adjustment of tax relating to earlier periods	7	-	-	7	184	184
	Total tax expenses	1 735	3 079	1 616	7 721	6 629	7 234
9.	**Net Profit for the period / year (7-8)**	6 118	9 090	4 656	23 441	18 420	20 098
10.	**Other Comprehensive Income**						
	Items that will not be reclassified to profit or loss						
	i. Re-measurement gains / (losses) on defined benefit plans	(107)	(266)	177	(350)	224	90
	ii.Income tax effect on above	27	67	(44)	88	(56)	(23)
	Other Comprehensive Income, net of tax	(80)	(199)	133	(262)	168	67
11.	**Total Comprehensive Income for the period / year (9+10)**	6 038	8 891	4 789	23 179	18 588	20 165
12.	Paid-up equity share capital (Face Value ₹ 10/- each)	1 660	1 660	1 660	1 660	1 660	1 660
13.	Other equity				52 036		52 164
14.	**Earnings per equity share (of ₹ 10/- each)**						
	***(not annualised)**						
	(a) Basic and Diluted (in ₹) (before exceptional items)	* 36.86	* 54.76	* 28.05	* 141.22	* 110.97	133.24
	(b) Basic and Diluted (in ₹) (after exceptional items)	* 36.86	* 54.76	* 28.05	* 141.22	* 110.97	121.07

Procter & Gamble Health Limited Mumbai

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.
CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

Notes:

1. The above audited financial results for the quarter and nine months financial year ended March 31, 2025 have been reviewed by the Audit Committee and taken on record in the meeting of the Board of Directors held on May 29, 2025 . These financial results have been subjected to an audit by the statutory auditors of the Company, who have expressed an unmodified opinion thereon. These financial results are prepared and published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement has been prepared in accordance with the Companies ("Indian Accounting Standards") Rules, 2015 ("IND AS") prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

3. The Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 - Operating Segments. Accordingly no separate segment information has been provided.

4. The Board of Directors of the Company, on January 23, 2025, approved the change of the Financial Year end from June 30th to March 31st. Accordingly, the current Financial Year of the Company viz., 2024-25 is for a period of nine months commencing on July 1, 2024, and ending on March 31, 2025. Due to this change of period, the figures of the current period are not comparable with those of the previous year.

5. a. The figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of nine months financial year ended March 31, 2025 and the limited reviewed year to date figures up to six months period ended December 31, 2024 of the current nine months Financial Year .
   b. For the purpose of comparibility, Figures for 9 month period ended 31 March 2024 have been presented in the audited financial results.

6. The audited financial results are available on the website of the Company (www.pghealthindia.com) and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com).

7. The Board of Directors at its meeting held on May 29th 2025, have recommended paymemt of final dividend of ₹ 45 per equity share (face value Rs.10) and aggregating to ₹ 7 469 lakhs and is payable subject to the approval of the shareholders at the annual general meeting.

8. During the quarter ended June 30, 2024, the Company had discontinued production of injections at its manufacturing plant in Goa effective September 30, 2023, as the Company had started to source injections portfolio of its products from a contract manufacturer. Post evaluation of various alternatives, during the quarter ended June 30, 2024, the Company had entered into an agreement for sale of the assets of its injection plant for a consideration of ₹ 790 Lakhs and impaired the balance amount of ₹ 627 Lakhs. Based on above, the company had re-evaluated the usability of assets in their capital work in progress and thereby impaired other related assets by an amount of ₹ 1 392 Lakhs. The above total amount of ₹ 2 019 Lakhs was disclosed as an exceptional item for the quarter and the year ended June 30, 2024.

9. Previous year's/period's figures have been regrouped/ rearranged/reclassified wherever necessary to conform to current period's classification.

10. The Company does not have a subsidiary, an associate or a joint venture as at 31st March, 2025.



For and on behalf of the Board of Directors of
Procter & Gamble Health Limited

Milind Thatte
Managing Director

Place : Mumbai
Date : May 29, 2025

PROCTER & GAMBLE HEALTH LIMITED

Statement of Assets and Liabilities

(₹ in lakhs)

Particulars	As at March 31, 2025 (Audited)	As at June 30, 2024 (Audited)
ASSETS		
Non-current assets		
(a) Property, plant and equipment	**10,463**	11,721
(b) Capital work-in-progress	**1,096**	589
(c) Investment property	**437**	190
(d) Right -of -use assets	**640**	843
(e) Intangible assets	**71**	96
(f) Financial assets		
(i) Loans	**1,017**	974
(ii) Other financial assets	**479**	624
(g) Deferred tax assets (net)	**3,506**	3,369
(h) Other non-current assets	**291**	189
(i) Non-current tax assets (net)	**8,781**	8,419
Total non-current assets	**26,781**	27,014
Current assets		
(a) Inventories	**10,937**	10,911
(b) Financial assets		
(i) Trade receivables	**14,540**	8,533
(ii) Cash and cash equivalents	**18,208**	23,850
(iii) Bank balances other than (ii) above	**647**	586
(iv) Loans	**159**	172
(v) Other financial assets	**1,751**	1,337
(c) Other current assets	**6,287**	6,133
(d) Assets held for Sale	**110**	900
Total current assets	**52,639**	52,422
TOTAL ASSETS	**79,420**	79,436
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	**1,660**	1,660
(b) Other equity	**52,036**	52,164
Total Equity	**53,696**	53,824
Non-Current Liabilities		
(a) Financial liabilities		
(i) Lease liabilities	**481**	688
(b) Provisions	**3,612**	2,964
(c) Other non-current liabilities	**100**	69
Total non-current liabilities	**4,193**	3,721
Current liabilities		
(a) Financial liabilities		
(i) Trade payables		
- Total outstanding dues of micro enterprises and small enterprises	**1,208**	912
- Total outstanding dues of creditors other than micro enterprises and small enterprises	**15,952**	15,788
(ii) Lease Liabilities	**281**	268
(iii) Other financial liabilities	**1,666**	2,301
(b) Provisions	**697**	1,024
(c) Current tax liabilities (net)	**345**	345
(d) Other current liabilities	**1,382**	1,253
Total current liabilities	**21,531**	21,891
Total liabilities	**25,724**	25,612
TOTAL EQUITY & LIABILITIES	**79,420**	79,436

Procter & Gamble Health Limited Mumbai

Procter & Gamble Health Limited

Statement of Cash Flows for the financial year (nine months) ended March 31, 2025

(₹ in lakhs)

Particulars	Financial Year (nine months) ended March 31, 2025 (Audited)	Financial Year (twelve months) ended June 30, 2024 (Audited)
A. Cash Flows from Operating Activities		
Profit before tax	**31 162**	**27 332**
Adjustments for:		
Net unrealised foreign exchange (Gain)/Loss	(35)	202
Allowance for doubtful receivables/ other assets	59	74
Provision for Inventory (net of reversals)	211	270
Provision/ write off of GST and other taxes	158	1 227
Depreciation and amortization expense	1,669	2 740
Provision for Impairment	-	2 019
Rental income	(310)	(210)
Provision for employee benefits	36	705
Provision for sales return/ expiries	-	(819)
Loss on sale of property, plant and equipment	13	51
Share-based payment to employees	80	69
Finance costs	43	72
Interest income	(704)	(1 173)
Operating profit before working capital changes	**32 382**	**32 559**
Working capital adjustments:		
(Increase)/Decrease in inventories	(237)	2 313
(Increase)/Decrease in trade receivables	(6 031)	2 917
(Increase)/Decrease in financial and other Assets	(724)	1 827
Increase/(Decrease) in trade payables	693	(7 161)
(Decrease)/Increase in other liabilities and provisions	(1 082)	(1 108)
Cash generated from operations	**25 001**	**31 348**
Income taxes paid (net)	(8 132)	(8 519)
Net cash flows generated from operating activities (A)	**16 869**	**22 829**
B. Cash Flows from Investing Activities		
Purchase and construction of property, plant & equipment, capital work-in-progress	(856)	(2 173)
Proceeds from disposal of property plant & equipment and assets held for sale	790	14
Rental income	310	210
Interest received	715	1 262
Net cash flows generated from/(used in) investing activities (B)	**959**	**(687)**
C. Cash flow from financing activities		
Dividend paid	(23 240)	(41 499)
Payment of lease liability	(234)	(312)
Net cash flows (used in) financing activities (C)	**(23 474)**	**(41 811)**
Net (decrease) in cash and cash equivalents (A+B+C)	**(5 646)**	**(19 669)**
Cash and cash equivalents at the beginning of the year	**23 873**	**43 542**
Cash and cash equivalents at the end of the year	**18 227**	**23 873**
Components of Cash and Cash equivalents at the end of the year:		
In Current accounts	**9 227**	**8 873**
In Term deposits (having original maturity of less than three months)	**9 000**	**15 000**
	18 227	**23 873**

Note:

The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS 7) - Statement of Cash Flows.

Procter & Gamble Health Limited Mumbai

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Procter & Gamble Health Limited

Report on the Audit of the Annual Financial Results

Opinion

We have audited the accompanying annual financial results of Procter & Gamble Health Limited ("the Company") for the nine months year ended March 31, 2025 ("the Statement") (refer note 4), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

(i) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards, and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the nine months year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Annual Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Statement under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Directors' Responsibilities for the Annual Financial Results

The Statement has been prepared on the basis of the annual financial statements. The Company's Management and the Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the

Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Management and the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Management and the Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made in the Statement by the Management and the Board of Directors.

HARIBHAKTI & CO. LLP ★ MUMBAI ★ CHARTERED ACCOUNTANTS

- Conclude on the appropriateness of the Management and the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended March 31, 2025, being the balancing figure between audited figures in respect of nine months year ended March 31, 2025 and the published unaudited year to date figures up to the six months period ended December 31, 2024 of the current financial year which were subject to limited review by us.

Our opinion is not modified in respect of this matter.

For Haribhakti & Co. LLP

Chartered Accountants

ICAI Firm Registration No.103523W / W100048

HARIBHAKTI & CO. LLP ★ MUMBAI ★ CHARTERED ACCOUNTANTS

Sumant Sakhardande

Partner

Membership No. 034828

UDIN: 25034828BMNZIX9972

Place: Mumbai
Date: May 29, 2025

May 29, 2025

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Symbol:- PGHL

Dear Sir/Madam,

Sub: Declaration with respect to Audit Report with unmodified opinion to the Audited Financial Results for the Financial Year ended March 31, 2025

We hereby declare that Audited Financial Results for the Financial Year ended March 31, 2025 which have been approved by the Board of Directors of the Company at meeting held today, i.e., May 29, 2025, the Statutory Auditors, Haribhakit & Co. LLP have not expressed any modified opinion(s) in their Audit Report.

The above declaration is made pursuant to Regulation 33 (3) (d) of the Securities Exchange and Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Thanking you.

For **Procter & Gamble Health Limited**

Zeal Bhavin Rupani
Digitally signed by Zeal Bhavin Rupani
Date: 2025.05.29 17:20:41 +05'30'

Zeal Rupani
Company Secretary

c